Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Mini-review of Available Evidence

Venkatesan Thiruvenkatarajan; Joshua M. Inglis; Emily Meyer; Mahesh M. Umapathysivam; Nagesh Nanjappa; Roelof Van Wijk; David Jesudason

doi:10.1016/j.jcjd.2022.12.003

Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Mini-review of Available Evidence

Venkatesan Thiruvenkatarajan, Joshua M. Inglis, Emily Meyer, Mahesh M. Umapathysivam, Nagesh Nanjappa, Roelof Van Wijk, David Jesudason

College of Medicine and Public Health

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a class of oral glucose-lowering agents commonly used for the treatment of type 2 diabetes. With increased use, there has been an increase in the incidence of the rare but life-threatening complication of euglycemic diabetic ketoacidosis. A common but underappreciated precipitant is colonoscopy. In this work, we outline the pathophysiology of the interaction between colonoscopy and SGLT2i use, the evidence regarding SGLT2i use in the periprocedural setting and Australian Diabetes Society guidelines.

Original language	English
Pages (from-to)	287-291
Number of pages	5
Journal	Canadian Journal of Diabetes
Volume	47
Issue number	3
Early online date	24 Dec 2022
DOIs	https://doi.org/10.1016/j.jcjd.2022.12.003
Publication status	Published - Apr 2023

Keywords

colonoscopy
diabetes
ketoacidosis
peri-colonoscopy
review
SGLT2i

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jcjd.2022.12.003Licence: In Copyright

Cite this

@article{bea7b9e22a2f484ea2c2e0c02a3f29ee,

title = "Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Mini-review of Available Evidence",

abstract = "Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a class of oral glucose-lowering agents commonly used for the treatment of type 2 diabetes. With increased use, there has been an increase in the incidence of the rare but life-threatening complication of euglycemic diabetic ketoacidosis. A common but underappreciated precipitant is colonoscopy. In this work, we outline the pathophysiology of the interaction between colonoscopy and SGLT2i use, the evidence regarding SGLT2i use in the periprocedural setting and Australian Diabetes Society guidelines.",

keywords = "colonoscopy, diabetes, ketoacidosis, peri-colonoscopy, review, SGLT2i",

author = "Venkatesan Thiruvenkatarajan and Inglis, {Joshua M.} and Emily Meyer and Umapathysivam, {Mahesh M.} and Nagesh Nanjappa and {Van Wijk}, Roelof and David Jesudason",

year = "2023",

month = apr,

doi = "10.1016/j.jcjd.2022.12.003",

language = "English",

volume = "47",

pages = "287--291",

journal = "Canadian Journal of Diabetes",

issn = "1499-2671",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy

T2 - A Mini-review of Available Evidence

AU - Thiruvenkatarajan, Venkatesan

AU - Inglis, Joshua M.

AU - Meyer, Emily

AU - Umapathysivam, Mahesh M.

AU - Nanjappa, Nagesh

AU - Van Wijk, Roelof

AU - Jesudason, David

PY - 2023/4

Y1 - 2023/4

N2 - Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a class of oral glucose-lowering agents commonly used for the treatment of type 2 diabetes. With increased use, there has been an increase in the incidence of the rare but life-threatening complication of euglycemic diabetic ketoacidosis. A common but underappreciated precipitant is colonoscopy. In this work, we outline the pathophysiology of the interaction between colonoscopy and SGLT2i use, the evidence regarding SGLT2i use in the periprocedural setting and Australian Diabetes Society guidelines.

AB - Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a class of oral glucose-lowering agents commonly used for the treatment of type 2 diabetes. With increased use, there has been an increase in the incidence of the rare but life-threatening complication of euglycemic diabetic ketoacidosis. A common but underappreciated precipitant is colonoscopy. In this work, we outline the pathophysiology of the interaction between colonoscopy and SGLT2i use, the evidence regarding SGLT2i use in the periprocedural setting and Australian Diabetes Society guidelines.

KW - colonoscopy

KW - diabetes

KW - ketoacidosis

KW - peri-colonoscopy

KW - review

KW - SGLT2i

UR - http://www.scopus.com/inward/record.url?scp=85147362567&partnerID=8YFLogxK

U2 - 10.1016/j.jcjd.2022.12.003

DO - 10.1016/j.jcjd.2022.12.003

M3 - Review article

C2 - 36739255

AN - SCOPUS:85147362567

SN - 1499-2671

VL - 47

SP - 287

EP - 291

JO - Canadian Journal of Diabetes

JF - Canadian Journal of Diabetes

IS - 3

ER -

Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Mini-review of Available Evidence

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this